Adherence and acceptability of once daily Lamivudine and abacavir in human immunodeficiency virus type-1 infected children.

Схожие документы

• Plasma pharmacokinetics of once- versus twice-daily lamivudine and abacavir: simplification of combination treatment in HIV-1-infected children (PENTA-13).
  по: Bergshoeff, A, и др.
  Опубликовано: (2005)
• Once- versus twice-daily abacavir and lamivudine in African children: the randomised controlled ARROW Trial
  по: Musiime, V, и др.
  Опубликовано: (2016)
• Pharmacokinetics and acceptability of once- versus twice-daily lamivudine and abacavir in HIV type-1-infected Ugandan children in the ARROW Trial.
  по: Musiime, V, и др.
  Опубликовано: (2010)
• Lamivudine/abacavir maintains virological superiority over zidovudine/lamivudine and zidovudine/abacavir beyond 5 years in children.
  по: Green, H, и др.
  Опубликовано: (2007)
• Plasma pharmacokinetics of once-daily abacavir- and lamivudine-containing regimens and week 96 efficacy in HIV-infected Thai children
  по: Torsak Bunupuradah, и др.
  Опубликовано: (2015-07-01)